Sökning: onr:"swepub:oai:DiVA.org:umu-187455" > Prolactin and risk ...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 06109naa a2200469 4500 | |
001 | oai:DiVA.org:umu-187455 | |
003 | SwePub | |
008 | 210913s2021 | |||||||||||000 ||eng| | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-1874552 URI |
024 | 7 | a https://doi.org/10.1158/1055-9965.EPI-21-01392 DOI |
040 | a (SwePub)umu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Hathaway, Cassandra A.u Department of Cancer Epidemiology, Moffitt Cancer Center, FL, Tampa, United States4 aut |
245 | 1 0 | a Prolactin and risk of epithelial ovarian cancer |
264 | 1 | b American Association for Cancer Research (AACR),c 2021 |
338 | a print2 rdacarrier | |
520 | a Background: Prolactin is synthesized in the ovaries and may play a role in ovarian cancer etiology. One prior prospective study observed a suggestive positive association between prolactin levels and risk of ovarian cancer.Methods: Weconducted a pooled case-control study of 703 cases and 864 matched controls nested within five prospective cohorts. We used unconditional logistic regression to calculate adjusted odds ratios (OR) and 95% confidence intervals (CI) for the association between prolactin and ovarian cancer risk. We examined heterogeneity by menopausal status at blood collection, body mass index (BMI), age, and histotype.Results: Among women with known menopausal status, we observed a positive trend in the association between prolactin and ovarian cancer risk (Ptrend = 0.045; OR, quartile 4 vs. 1 = 1.34; 95% CI = 0.97–1.85), but no significant association was observed for premenopausal or postmenopausal women individually (corresponding OR = 1.38; 95% CI = 0.74–2.58; Ptrend = 0.32 and OR = 1.41; 95% CI = 0.93–2.13; Ptrend = 0.08, respectively; Pheterogeneity = 0.91). In stratified analyses, we observed a positive association between prolactin and risk for women with BMI ≥ 25 kg/m2, but not BMI < 25 kg/m2 (corresponding OR = 2.68; 95% CI = 1.56–4.59; Ptrend < 0.01 and OR = 0.90; 95% CI = 0.58–1.40; Ptrend = 0.98, respectively; Pheterogeneity < 0.01). Associations did not vary by age, postmenopausal hormone therapy use, histotype, or time between blood draw and diagnosis.Conclusions: We found a trend between higher prolactin levels and increased ovarian cancer risk, especially among women with a BMI ≥ 25 kg/m2.Impact: This work supports a previous study linking higher prolactin with ovarian carcinogenesis in a high adiposity setting. Future work is needed to understand the mechanism underlying this association. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Hälsovetenskapx Folkhälsovetenskap, global hälsa, socialmedicin och epidemiologi0 (SwePub)303022 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Health Sciencesx Public Health, Global Health, Social Medicine and Epidemiology0 (SwePub)303022 hsv//eng |
700 | 1 | a Rice, Megan S.u Clinical and Translational Epidemiology Unit, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, MA, Boston, United States4 aut |
700 | 1 | a Townsend, Mary K.u Department of Cancer Epidemiology, Moffitt Cancer Center, FL, Tampa, United States4 aut |
700 | 1 | a Hankinson, Susan E.u Department of Biostatistics and Epidemiology, School of Public Health and Health Sciences, University of Massachusetts Amherst, MA, Amherst, United States4 aut |
700 | 1 | a Arslan, Alan A.u Department of Obstetrics and Gynecology, New York University Langone Health, NY, New York, United States; Department of Population Health, New York University Langone Health, NY, New York, United States; NYU Perlmutter Comprehensive Cancer Center, NY, New York, United States4 aut |
700 | 1 | a Buring, Julie E.u Division of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, MA, Boston, United States; Department of Epidemiology, Harvard T.H. Chan School of Public Health, MA, Boston, United States4 aut |
700 | 1 | a Hallmans, Göran,d 1947-u Umeå universitet,Näringsforskning4 aut0 (Swepub:umu)goha0001 |
700 | 1 | a Idahl, Annika,d 1965-u Umeå universitet,Obstetrik och gynekologi4 aut0 (Swepub:umu)anid0002 |
700 | 1 | a Kubzansky, Laura D.u Department of Epidemiology, Harvard T.H. Chan School of Public Health, MA, Boston, United States4 aut |
700 | 1 | a Lee, I-Minu Division of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, MA, Boston, United States; Department of Epidemiology, Harvard T.H. Chan School of Public Health, MA, Boston, United States4 aut |
700 | 1 | a Lundin, Evau Umeå universitet,Patologi4 aut0 (Swepub:umu)evlu0001 |
700 | 1 | a Sluss, Patrick M.u Department of Pathology, Massachusetts General Hospital, MA, Boston, United States4 aut |
700 | 1 | a Zeleniuch-Jacquotte, Anneu Department of Population Health, New York University Langone Health, NY, New York, United States; NYU Perlmutter Comprehensive Cancer Center, NY, New York, United States4 aut |
700 | 1 | a Tworoger, Shelley S.u Department of Cancer Epidemiology, Moffitt Cancer Center, FL, Tampa, United States; Department of Epidemiology, Harvard T.H. Chan School of Public Health, MA, Boston, United States4 aut |
710 | 2 | a Department of Cancer Epidemiology, Moffitt Cancer Center, FL, Tampa, United Statesb Clinical and Translational Epidemiology Unit, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, MA, Boston, United States4 org |
773 | 0 | t Cancer Epidemiology, Biomarkers and Preventiond : American Association for Cancer Research (AACR)g 30:9, s. 1652-1659q 30:9<1652-1659x 1055-9965x 1538-7755 |
856 | 4 | u https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419083/y PMC free full text |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-187455 |
856 | 4 8 | u https://doi.org/10.1158/1055-9965.EPI-21-0139 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.